Bali Muralidhar

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland.

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO.

Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022.

Stryve Online Ltd. is a British company that offers an applicant tracking system designed to improve the hiring process. The company is based in London, UK. The platform is equipped with various features that aim to make the process more efficient. It was founded in 2019 by Edward Chamberlain.

Launch Therapeutics, Inc. provides investment and therapies development services. The CEO of the American company is Anshul Thakral.